Acurx Pharmaceuticals, Inc. Annual report [Section 13 and 15(d), not S-K Item 405]

Annual report [Section 13 and 15(d), not S-K Item 405]

NATURE OF OPERATIONS (Details)

NATURE OF OPERATIONS (Details) - USD ($)									1 Months Ended	12 Months Ended
NATURE OF OPERATIONS (Details) - USD ($)	Jun. 17, 2025	May 08, 2025	Mar. 06, 2025	Jan. 06, 2025	Nov. 15, 2023	May 18, 2023	Jul. 27, 2022	Jun. 29, 2021	Feb. 28, 2018	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023	Jun. 23, 2021
Class of Stock [Line Items]
Shares issued (in shares)						30,093	57,961	143,750
Share price (in dollars per share)								$ 120
Pre-funded Warrant Exercise (in shares)						36,574	6,538
Gross proceeds from stock issue						$ 4,000,000	$ 4,200,000	$ 17,300,000
Common stock, par value										$ 0.001	$ 0.001		$ 0.001
Proceeds from Warrant Exercise										$ 1,360,544	$ 210,199
Cash										$ 7,556,100	$ 3,706,713
Series A warrants
Class of Stock [Line Items]
Number of warrants							64,499
Series B warrants
Class of Stock [Line Items]
Number of warrants							64,499
Series C warrants
Class of Stock [Line Items]
Number of warrants						66,667
Series D warrants
Class of Stock [Line Items]
Number of warrants						66,667
At the Market Offering
Class of Stock [Line Items]
Shares issued (in shares)											106,610	894
Share price (in dollars per share)											$ 62
Aggregate offering price					$ 17,000,000						$ 7,800,000
Gross proceeds from stock issue											$ 6,600,000
At the Market Offering \| Aggregate
Class of Stock [Line Items]
Shares issued (in shares)											141,516
Gross proceeds from stock issue											$ 9,200,000
Equity Line of Credit Purchase Agreement
Class of Stock [Line Items]
Shares issued (in shares)		751,397
Share price (in dollars per share)		$ 5.26
Gross proceeds from stock issue		$ 3,953,430
Aggregate value of shares committed for purchase		12,000,000
Equity Line of Credit Purchase Agreement \| Common Stock
Class of Stock [Line Items]
Shares issued (in shares)										751,397
Gross proceeds from stock issue										$ 4,000,000
Aggregate value of shares committed for purchase		$ 12,000,000
Common stock, par value		$ 0.001
Warrant Inducement Agreement
Class of Stock [Line Items]
Warrant exercise price (in dollars per share)	$ 12
Gross proceeds from stock issue	$ 2,700,000
Proceeds from Warrant Exercise	$ 2,700,000
Warrant Inducement Agreement \| Series A warrants
Class of Stock [Line Items]
Warrant exercise price (in dollars per share)	$ 65
Warrant Inducement Agreement \| Series B warrants
Class of Stock [Line Items]
Warrant exercise price (in dollars per share)	65
Warrant Inducement Agreement \| Series C warrants
Class of Stock [Line Items]
Warrant exercise price (in dollars per share)	65.2
Warrant Inducement Agreement \| Series D warrants
Class of Stock [Line Items]
Warrant exercise price (in dollars per share)	$ 65.2
January 2025 Registered Direct Offering
Class of Stock [Line Items]
Shares issued (in shares)				123,153
Share price (in dollars per share)				$ 20.3
Gross proceeds from stock issue				$ 2,500,000
March 2025 Registered Direct Offering
Class of Stock [Line Items]
Shares issued (in shares)			107,500
Share price (in dollars per share)			$ 8
Gross proceeds from stock issue			$ 1,100,000
ACX362E
Class of Stock [Line Items]
Cash paid									$ 110,174
Future commitment									700,000
Royalty payments									$ 200,000		$ 150,000
Royalty payments on net sales (as a percent)									4.00%
ACX362E \| Members' Equity, Class B
Class of Stock [Line Items]
Granting (in shares)									100,000
Warrant exercise price (in dollars per share)									$ 0.1